Ethyl-Eicosapentaenoic Acid and Tardive Dyskinesia
Status:
Completed
Trial end date:
2005-03-01
Target enrollment:
Participant gender:
Summary
Tardive dyskinesia is a common complication of conventional antipsychotic treatment in
subjects with schizophrenia. This study investigates whether the addition of the omega-3
fatty acid, ethyl-eicosapentaenoic acid (EPA) to usual treatment improves movement disorder
in 84 schizophrenia subjects with established tardive dyskinesia. The initial double-blinded,
randomised trial duration is 12 weeks, followed by further 46 weeks of open-label treatment.